Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
5
83%

Phase Distribution

0

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Not yet recruiting2
Recruiting2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (83.3%)
Phase 31 (16.7%)

Trials by Status

not_yet_recruiting233%
completed117%
recruiting233%
active_not_recruiting117%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_2

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

NCT03859128
completedphase_3

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

NCT03924050
not_yet_recruitingphase_2

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

NCT06919848
not_yet_recruitingphase_2

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

NCT06903871
recruitingphase_2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

NCT06889649
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03859128Phase 2

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection

Active Not Recruiting
NCT03924050Phase 3

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Completed
NCT06919848Phase 2

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Not Yet Recruiting
NCT06903871Phase 2

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

Not Yet Recruiting
NCT06889649Phase 2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Recruiting
NCT06705127Phase 2

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6